- About Us
- Our BioBank Platform Technology
- Our Drug Programmes
- Contact us
Date of last update: 26 October 2021
Where guidance is given to see another section of the website, please click on the highlighted word.
Synairgen is a drug discovery company focused on identifying and out-licensing new pharmaceutical products which address the underlying causes of asthma, chronic obstructive pulmonary disease (COPD) and other respiratory diseases. Please also see Technology and Programmes sections for further details.
See Directors section.
See Directors section for responsibilities of the members of the board of directors.
There are two committees of the Board:
The Audit Committee comprises Simon Shaw (Chairman), Iain Buchanan and Dr Bruce Campbell. The committee has primary responsibility for ensuring that the financial performance of the Group is properly measured and reported on, reviewing the interim financial information and annual financial statements before they are submitted to the Board. The committee also reviews, and reports on, reports from the Group’s auditors relating to the Group’s accounting controls. It makes recommendations to the Board on the appointment of auditors and the audit fee. The committee monitors the scope, results and cost-effectiveness of the audit. It has unrestricted access to the Group’s auditors. In certain circumstances it is permitted by the Board for the auditors to supply non-audit services (in the provision of tax advice, or on specific projects where they can add value). The committee monitors the application of this policy in order to safeguard auditor objectivity and independence.
The Remuneration and Nomination Committee comprises Iain Buchanan (Chairman), Simon Shaw and Dr Bruce Campbell. The committee is responsible for making recommendations to the Board on remuneration policy for executive directors and the terms of their service contracts, with the aim of ensuring that their remuneration, including any share options and other awards, is based on their own performance and that of the Group generally. The committee administers the Long-Term Incentive Plan and the staff share option scheme and approves grants under both schemes. It also advises on the remuneration policy for the Group’s employees. The committee is responsible for all senior appointments that are made within the Group.
Synairgen plc is incorporated in England and its main country of operation is England.
The Company’s issued share capital consists of 201,341,825 ordinary shares with a nominal value of 1p each, each share having equal voting rights.
The Company does not hold any ordinary shares in treasury and therefore the total number of ordinary shares with voting rights is 201,341,825.
Shareholders with interests of over 3% (Significant Shareholders), as advised to the Company, are listed below.
|Name of shareholder||Number of ordinary shares||% of share capital|
|Polygon Global Partners LLP||28,635,221||14.2%|
|Polar Capital LLP||15,706,535||7.8%|
In so far as the Company is aware, the percentage of the Company’s issued share capital that is not in public hands is 16.7%, which comprises the holding of Polygon Global Partners LLP and the directors’ beneficial holdings
The Company is subject to the provisions of the UK City Code on Takeovers and Mergers.
The Board is accountable to the Company’s shareholders for good corporate governance and it is the objective of the Board to attain a high standard of corporate governance. The Board has adopted the Quoted Companies Alliance Corporate Governance Code (QCA Code) and the Corporate Governance Statement sets out how the Group complies with the 10 Principles of the QCA Code.
For copies of the annual and interim reports please see Financials section.
See News section
Notice of the 2018 AGM was sent to shareholders on 17 May 2018. The Notice was included on page 49 of the 2017 annual report and accounts and a link to this document is provided here.
For details of our nominated adviser and other key advisers please see Advisers section